Navigation Links
AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
Date:7/17/2013

LOS ALTOS, Calif., July 17, 2013 /PRNewswire-iReach/ -- AbGenomics International announced today that it has raised $9.6 million in current financing round. 

(Photo: http://photos.prnewswire.com/prnh/20130717/MN49038)

AbGenomics will use the proceeds to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics' lead drug candidate AbGn-168H, a first-in-class humanized monoclonal antibody that specifically depletes chronic activated T cells for the treatment of autoimmune diseases, is in Phase II clinical trials for psoriasis. The evaluation of additional AbGn-168H trials for Crohn's/IBD, type-I diabetes, MS, and RA indications are ongoing. The company plans to advance another therapeutic candidate, AbGn-107, an antibody drug conjugate with fully owned first-in-class linker-payload, into phase-I clinical trial for the treatment of pancreatic and stomach tumors early next  year.  "We are delighted to have the continuing support of our investors. This round of financing provides AbGenomics additional capital to continue its clinical-stage programs through proof of concept for addressing major unmet needs in autoimmune diseases and advance its first-in-class antibody drug conjugate technology for cancers." said Dr. Rong-Hwa Lin, Founder and CEO of AbGenomics.

About AbGenomics (www.abgenomics.com) AbGenomics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds.

Media Contact: RUTH LI, ABGENOMICS INTERNATIONAL INC., 6509889912, RUTH.LI@ABGENOMICS.COM

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE AbGenomics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
5. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
6. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
7. Chindex International, Inc. to Report First Quarter 2012 Financial Results
8. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
9. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Bacterin International Signs Its Third National GPO Contract with Novation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):